Tag: ADC Therapeutics
ADC Therapeutics and Mitsubishi Tanabe Pharma Sign Exclusive License Agreement to...
ADC Therapeutics and Mitsubishi Tanabe Pharma Corporation have signed an exclusive license agreement for the development and commercialization of loncastuximab tesirine (ADCT-402; Zynlonta®; ADC...
Sterling Pharma Solutions Acquires ADC Biotechnology
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has announced the acquisition of ADC Biotechnology, a UK-based bioconjugation development services business specializing...
U.S. FDA Accepts Biologics License Application and Grants Priority Review for...
The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for loncastuximab tesirine, previously known as ADCT-402.
The investigational agent is...
FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab...
The U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) from ADC Therapeutics for loncastuximab tesirine, previously know as ADCT-402,...
Synaffix and ADC Therapeutics Expand Collaboration
The Netherlands-based biotechnology company Synaffix and Swiss-based ADC Therapeutics have expanded the existing collaboration between the companies to explore additional applications of Synaffix’ site-specific...
FDA Lifts Partial Clinical Hold on Pivotal Phase II Clinical Trial...
Earlier this week the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold on the pivotal Phase II clinical study of camidanlumab...
Loncastuximab Tesirine Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin...
Loncastuximab tesirine, also known as ADCT-402, an investigational antibody-drug conjugate being developed by ADC Therapeutics, showed signs of clinical activity in patients with relapsed/refractory...
Freenome Enters Biomarker Development Collaboration with ADC Therapeutics
Swiss-based ADC Therapeutics, an oncology-drug development company specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotech company pioneering the a...
SOPHiA Genetics and ADC Therapeutics Partner for Biomarker Discovery in Pivotal...
ADC Therapeutics and SOPHiA GENETICS have entered into a collaboration to identify genomic markers associated with clinical response to loncastuximab tesirine (ADCT-402), an antibody...
Pyrrolobenzodiazepine-based ADCs Demonstrate Potential in R/R Lymphomas
The International Conference on Malignant Lymphoma (ICML) has, since its first edition in 1981, become one of the must-attend conferences for the scientific community...
